Xiamen Amoytop Biotech Co., Ltd. (688278.SS)
CNY 74.3
(-1.72%)
CNY 74.3
(-1.72%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.27 Billion CNY | 48.03% |
| 2022 | 959.54 Million CNY | 25.05% |
| 2021 | 767.35 Million CNY | 37.85% |
| 2020 | 556.65 Million CNY | 6.46% |
| 2019 | 522.86 Million CNY | 49.16% |
| 2018 | 350.53 Million CNY | 33.28% |
| 2017 | 263 Million CNY | 24.68% |
| 2016 | 210.93 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 339.34 Million CNY | -76.12% |
| 2024 Q3 | 427.68 Million CNY | 9.22% |
| 2024 Q2 | 390.25 Million CNY | 15.0% |
| 2023 Q4 | 1.42 Billion CNY | 347.69% |
| 2023 FY | 1.42 Billion CNY | 48.03% |
| 2023 Q3 | 317.4 Million CNY | 3.13% |
| 2023 Q1 | 265.18 Million CNY | 8.55% |
| 2023 Q2 | 307.77 Million CNY | 16.06% |
| 2022 Q1 | 221.79 Million CNY | 0.64% |
| 2022 FY | 959.54 Million CNY | 25.05% |
| 2022 Q4 | 244.3 Million CNY | -11.13% |
| 2022 Q3 | 274.9 Million CNY | 25.79% |
| 2022 Q2 | 218.53 Million CNY | -1.47% |
| 2021 Q3 | 227.14 Million CNY | 30.05% |
| 2021 Q4 | 220.37 Million CNY | -2.98% |
| 2021 Q2 | 174.66 Million CNY | 20.32% |
| 2021 Q1 | 145.16 Million CNY | -11.87% |
| 2021 FY | 767.35 Million CNY | 37.85% |
| 2020 Q4 | 164.72 Million CNY | 17.0% |
| 2020 Q1 | 129.6 Million CNY | -4.02% |
| 2020 Q2 | 121.5 Million CNY | -6.25% |
| 2020 Q3 | 140.78 Million CNY | 15.87% |
| 2020 FY | 556.65 Million CNY | 6.46% |
| 2019 Q1 | 116.46 Million CNY | 24.35% |
| 2019 FY | 522.86 Million CNY | 49.16% |
| 2019 Q4 | 135.03 Million CNY | -5.22% |
| 2019 Q3 | 142.47 Million CNY | 10.59% |
| 2019 Q2 | 128.82 Million CNY | 10.62% |
| 2018 Q3 | 95.36 Million CNY | 0.0% |
| 2018 Q4 | 93.65 Million CNY | -1.79% |
| 2018 FY | 350.53 Million CNY | 33.28% |
| 2017 FY | 263 Million CNY | 24.68% |
| 2016 FY | 210.93 Million CNY | 0.0% |